This review is a summary of evidence in support of nintedanib use in the treatment of idiopathic pulmonary fibrosis (IPF). The review focuses on the pathophysiology, epidemiology and management of IPF, and on the pharmacological, clinical, and safety profiles of nintedanib.
Independent expert commentary by Associate Professor Dan Chambers Prince Charles Hospital, and School of Medicine, The University of Queensland, Brisbane, Queensland.
Please login below to download this issue (PDF)